Therapeutic Options in High-risk Non-muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Guerin
SourceEuropean Urology, 67, 3, (2015), pp. 359-360
Article / Letter to editor
Display more detailsDisplay less details
SubjectRadboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences
Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guerin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.